Loading…

Personalized radiation dosimetry for PRRT—how many scans are really required?

Purpose Over recent years, peptide receptor radiotherapy (PRRT) has been recognized as an effective treatment for patients with metastatic neuroendocrine tumors (NETs). Personalized dosimetry can contribute to improve the outcome of peptide receptor radiotherapy (PRRT) in patients with metastatic NE...

Full description

Saved in:
Bibliographic Details
Published in:EJNMMI physics 2020-05, Vol.7 (1), p.26-26, Article 26
Main Authors: Freedman, Nanette, Sandström, Mattias, Kuten, Jonathan, Shtraus, Natan, Ospovat, Inna, Schlocker, Albert, Even-Sapir, Einat
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3
cites cdi_FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3
container_end_page 26
container_issue 1
container_start_page 26
container_title EJNMMI physics
container_volume 7
creator Freedman, Nanette
Sandström, Mattias
Kuten, Jonathan
Shtraus, Natan
Ospovat, Inna
Schlocker, Albert
Even-Sapir, Einat
description Purpose Over recent years, peptide receptor radiotherapy (PRRT) has been recognized as an effective treatment for patients with metastatic neuroendocrine tumors (NETs). Personalized dosimetry can contribute to improve the outcome of peptide receptor radiotherapy (PRRT) in patients with metastatic NETs. Dosimetry can aid treatment planning, ensuring that absorbed dose to vulnerable normal organs (kidneys and bone marrow) does not exceed safe limits over serial treatments, and that absorbed dose to tumor is sufficient. Absorbed dose is estimated from a series of post-treatment SPECT/CT images. Total self-dose is proportional to the integral under the time activity concentration curve (TACC). Method dependence of image-based absorbed dose calculations has been previously investigated, and we set out here to extend previous work by examining implications of number of data points in the TACC and the numerical integration methods used in estimating absorbed dose. Methods In this retrospective study, absorbed dose estimates and effective half-lives were calculated by fitting curves to TACCs for normal organs and tumors in 30 consecutive patients who underwent a series of 4 post-treatment SPECT/CT scans at 4 h, 24 h, 4–5 days, and 1 week following 177 Lu-DOTATATE PRRT. We examined the effects of including only 2 or 3 rather than all 4 data points in the TACC, and the effect of numerical integration method (mono-exponential alone or in combination with trapezoidal rule) on the absorbed dose and half-life estimates. Our current method is the combination of trapezoidal rule over the first 24 h, with mono-exponential fit thereafter extrapolated to infinity. The other methods were compared to this current method. Results Differences in absorbed dose and effective half-life between the current method and estimates based only on the second, third, and fourth scans were very small (mean differences < 2.5%), whereas differences between the current method and 4-point mono-exponential fit were higher (mean differences < 5%) with a larger range. It appears that in a 4-point mono-exponential fit the early (4 h) time point may skew results, causing some large errors. Differences between the current method and values based on only 2 time points were relatively small (mean differences < 3.5%) when the 24 h and 1 week scans were used, but when the 24 h and 4–5 days scans, or the 4–5 days and 1 week scans were used, differences were greater. Conclusion This study indicates that for
doi_str_mv 10.1186/s40658-020-00293-z
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cd307c1f09cd4567a520d61080c066ec</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cd307c1f09cd4567a520d61080c066ec</doaj_id><sourcerecordid>2401805530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3</originalsourceid><addsrcrecordid>eNp9kstu1DAUhiMEolXpC7BAkdiwIHB8i-MNqCq3SpVaVYWt5bFPph5l4tZOqGZWPARPyJPgTobSYcHKls93Pt_-onhO4A0hTf02cahFUwGFCoAqVq0fFfuUKFlJVvPHD-Z7xWFKCwAgVNSU0KfFHqNMcZBivzg7x5hCbzq_RldG47wZfOhLF5Jf4hBXZRtieX5xcfnrx8-rcFsuTb8qkzV9Kk3EMqLpulUebkYf0b1_VjxpTZfwcDseFF8_fbw8_lKdnn0-OT46rWzN-VAxJ1BZwnDGW9K2DTDZoKQoTCtF66yqjW0VZ1JZhRzQcFWLtlENZ7OZIoYdFCeT1wWz0NfRL01c6WC83iyEONcmDt52qK1jIC1pQVnHRS2NoOBqAg1YqGu02fV6cqVbvB5nO7YP_tvRxjaOOh8HCMv4uwnP7BKdxX6Iptvp2q30_krPw3ctKeGiuRO82gpiuBkxDXrpk8WuMz2GMWnKgTQgBIOMvvwHXYQx5u_aUNAoAlJlik6UjSGliO39YQjou7ToKS06p0Vv0qLXuenFw2vct_zJRgbY9llyqZ9j_Lv3f7S_AVWnzGI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2400891079</pqid></control><display><type>article</type><title>Personalized radiation dosimetry for PRRT—how many scans are really required?</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><creator>Freedman, Nanette ; Sandström, Mattias ; Kuten, Jonathan ; Shtraus, Natan ; Ospovat, Inna ; Schlocker, Albert ; Even-Sapir, Einat</creator><creatorcontrib>Freedman, Nanette ; Sandström, Mattias ; Kuten, Jonathan ; Shtraus, Natan ; Ospovat, Inna ; Schlocker, Albert ; Even-Sapir, Einat</creatorcontrib><description>Purpose Over recent years, peptide receptor radiotherapy (PRRT) has been recognized as an effective treatment for patients with metastatic neuroendocrine tumors (NETs). Personalized dosimetry can contribute to improve the outcome of peptide receptor radiotherapy (PRRT) in patients with metastatic NETs. Dosimetry can aid treatment planning, ensuring that absorbed dose to vulnerable normal organs (kidneys and bone marrow) does not exceed safe limits over serial treatments, and that absorbed dose to tumor is sufficient. Absorbed dose is estimated from a series of post-treatment SPECT/CT images. Total self-dose is proportional to the integral under the time activity concentration curve (TACC). Method dependence of image-based absorbed dose calculations has been previously investigated, and we set out here to extend previous work by examining implications of number of data points in the TACC and the numerical integration methods used in estimating absorbed dose. Methods In this retrospective study, absorbed dose estimates and effective half-lives were calculated by fitting curves to TACCs for normal organs and tumors in 30 consecutive patients who underwent a series of 4 post-treatment SPECT/CT scans at 4 h, 24 h, 4–5 days, and 1 week following 177 Lu-DOTATATE PRRT. We examined the effects of including only 2 or 3 rather than all 4 data points in the TACC, and the effect of numerical integration method (mono-exponential alone or in combination with trapezoidal rule) on the absorbed dose and half-life estimates. Our current method is the combination of trapezoidal rule over the first 24 h, with mono-exponential fit thereafter extrapolated to infinity. The other methods were compared to this current method. Results Differences in absorbed dose and effective half-life between the current method and estimates based only on the second, third, and fourth scans were very small (mean differences &lt; 2.5%), whereas differences between the current method and 4-point mono-exponential fit were higher (mean differences &lt; 5%) with a larger range. It appears that in a 4-point mono-exponential fit the early (4 h) time point may skew results, causing some large errors. Differences between the current method and values based on only 2 time points were relatively small (mean differences &lt; 3.5%) when the 24 h and 1 week scans were used, but when the 24 h and 4–5 days scans, or the 4–5 days and 1 week scans were used, differences were greater. Conclusion This study indicates that for 177 Lu-DOTATATE PRRT, accurate estimates of absorbed dose for organs and tumors may be estimated from scans at 24 h, 72 h, and 1 week post-treatment without an earlier scan. It may even be possible to cut out the 72 h scan, though the uncertainty increases. However, further work on more patients is required to validate this.</description><identifier>ISSN: 2197-7364</identifier><identifier>EISSN: 2197-7364</identifier><identifier>DOI: 10.1186/s40658-020-00293-z</identifier><identifier>PMID: 32394075</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>177Lu-DOTATATE ; Applied and Technical Physics ; Bone marrow ; Computational Mathematics and Numerical Analysis ; Computed tomography ; Curve fitting ; Data points ; Dosimeters ; Dosimetry ; Engineering ; Estimates ; Half-life ; Imaging ; Lutetium isotopes ; Mathematical analysis ; Medical imaging ; Medicine ; Medicine &amp; Public Health ; Metastasis ; Method dependence ; Methods ; Neuroendocrine tumors ; Nuclear Medicine ; Numerical integration ; Numerical methods ; Organs ; Peptides ; Radiation therapy ; Radiology ; Receptors ; Short Communication ; Tumors</subject><ispartof>EJNMMI physics, 2020-05, Vol.7 (1), p.26-26, Article 26</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3</citedby><cites>FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2400891079/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2400891079?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32394075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-437013$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Freedman, Nanette</creatorcontrib><creatorcontrib>Sandström, Mattias</creatorcontrib><creatorcontrib>Kuten, Jonathan</creatorcontrib><creatorcontrib>Shtraus, Natan</creatorcontrib><creatorcontrib>Ospovat, Inna</creatorcontrib><creatorcontrib>Schlocker, Albert</creatorcontrib><creatorcontrib>Even-Sapir, Einat</creatorcontrib><title>Personalized radiation dosimetry for PRRT—how many scans are really required?</title><title>EJNMMI physics</title><addtitle>EJNMMI Phys</addtitle><addtitle>EJNMMI Phys</addtitle><description>Purpose Over recent years, peptide receptor radiotherapy (PRRT) has been recognized as an effective treatment for patients with metastatic neuroendocrine tumors (NETs). Personalized dosimetry can contribute to improve the outcome of peptide receptor radiotherapy (PRRT) in patients with metastatic NETs. Dosimetry can aid treatment planning, ensuring that absorbed dose to vulnerable normal organs (kidneys and bone marrow) does not exceed safe limits over serial treatments, and that absorbed dose to tumor is sufficient. Absorbed dose is estimated from a series of post-treatment SPECT/CT images. Total self-dose is proportional to the integral under the time activity concentration curve (TACC). Method dependence of image-based absorbed dose calculations has been previously investigated, and we set out here to extend previous work by examining implications of number of data points in the TACC and the numerical integration methods used in estimating absorbed dose. Methods In this retrospective study, absorbed dose estimates and effective half-lives were calculated by fitting curves to TACCs for normal organs and tumors in 30 consecutive patients who underwent a series of 4 post-treatment SPECT/CT scans at 4 h, 24 h, 4–5 days, and 1 week following 177 Lu-DOTATATE PRRT. We examined the effects of including only 2 or 3 rather than all 4 data points in the TACC, and the effect of numerical integration method (mono-exponential alone or in combination with trapezoidal rule) on the absorbed dose and half-life estimates. Our current method is the combination of trapezoidal rule over the first 24 h, with mono-exponential fit thereafter extrapolated to infinity. The other methods were compared to this current method. Results Differences in absorbed dose and effective half-life between the current method and estimates based only on the second, third, and fourth scans were very small (mean differences &lt; 2.5%), whereas differences between the current method and 4-point mono-exponential fit were higher (mean differences &lt; 5%) with a larger range. It appears that in a 4-point mono-exponential fit the early (4 h) time point may skew results, causing some large errors. Differences between the current method and values based on only 2 time points were relatively small (mean differences &lt; 3.5%) when the 24 h and 1 week scans were used, but when the 24 h and 4–5 days scans, or the 4–5 days and 1 week scans were used, differences were greater. Conclusion This study indicates that for 177 Lu-DOTATATE PRRT, accurate estimates of absorbed dose for organs and tumors may be estimated from scans at 24 h, 72 h, and 1 week post-treatment without an earlier scan. It may even be possible to cut out the 72 h scan, though the uncertainty increases. However, further work on more patients is required to validate this.</description><subject>177Lu-DOTATATE</subject><subject>Applied and Technical Physics</subject><subject>Bone marrow</subject><subject>Computational Mathematics and Numerical Analysis</subject><subject>Computed tomography</subject><subject>Curve fitting</subject><subject>Data points</subject><subject>Dosimeters</subject><subject>Dosimetry</subject><subject>Engineering</subject><subject>Estimates</subject><subject>Half-life</subject><subject>Imaging</subject><subject>Lutetium isotopes</subject><subject>Mathematical analysis</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metastasis</subject><subject>Method dependence</subject><subject>Methods</subject><subject>Neuroendocrine tumors</subject><subject>Nuclear Medicine</subject><subject>Numerical integration</subject><subject>Numerical methods</subject><subject>Organs</subject><subject>Peptides</subject><subject>Radiation therapy</subject><subject>Radiology</subject><subject>Receptors</subject><subject>Short Communication</subject><subject>Tumors</subject><issn>2197-7364</issn><issn>2197-7364</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kstu1DAUhiMEolXpC7BAkdiwIHB8i-MNqCq3SpVaVYWt5bFPph5l4tZOqGZWPARPyJPgTobSYcHKls93Pt_-onhO4A0hTf02cahFUwGFCoAqVq0fFfuUKFlJVvPHD-Z7xWFKCwAgVNSU0KfFHqNMcZBivzg7x5hCbzq_RldG47wZfOhLF5Jf4hBXZRtieX5xcfnrx8-rcFsuTb8qkzV9Kk3EMqLpulUebkYf0b1_VjxpTZfwcDseFF8_fbw8_lKdnn0-OT46rWzN-VAxJ1BZwnDGW9K2DTDZoKQoTCtF66yqjW0VZ1JZhRzQcFWLtlENZ7OZIoYdFCeT1wWz0NfRL01c6WC83iyEONcmDt52qK1jIC1pQVnHRS2NoOBqAg1YqGu02fV6cqVbvB5nO7YP_tvRxjaOOh8HCMv4uwnP7BKdxX6Iptvp2q30_krPw3ctKeGiuRO82gpiuBkxDXrpk8WuMz2GMWnKgTQgBIOMvvwHXYQx5u_aUNAoAlJlik6UjSGliO39YQjou7ToKS06p0Vv0qLXuenFw2vct_zJRgbY9llyqZ9j_Lv3f7S_AVWnzGI</recordid><startdate>20200511</startdate><enddate>20200511</enddate><creator>Freedman, Nanette</creator><creator>Sandström, Mattias</creator><creator>Kuten, Jonathan</creator><creator>Shtraus, Natan</creator><creator>Ospovat, Inna</creator><creator>Schlocker, Albert</creator><creator>Even-Sapir, Einat</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><general>SpringerOpen</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FG</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>HCIFZ</scope><scope>P5Z</scope><scope>P62</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>20200511</creationdate><title>Personalized radiation dosimetry for PRRT—how many scans are really required?</title><author>Freedman, Nanette ; Sandström, Mattias ; Kuten, Jonathan ; Shtraus, Natan ; Ospovat, Inna ; Schlocker, Albert ; Even-Sapir, Einat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>177Lu-DOTATATE</topic><topic>Applied and Technical Physics</topic><topic>Bone marrow</topic><topic>Computational Mathematics and Numerical Analysis</topic><topic>Computed tomography</topic><topic>Curve fitting</topic><topic>Data points</topic><topic>Dosimeters</topic><topic>Dosimetry</topic><topic>Engineering</topic><topic>Estimates</topic><topic>Half-life</topic><topic>Imaging</topic><topic>Lutetium isotopes</topic><topic>Mathematical analysis</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metastasis</topic><topic>Method dependence</topic><topic>Methods</topic><topic>Neuroendocrine tumors</topic><topic>Nuclear Medicine</topic><topic>Numerical integration</topic><topic>Numerical methods</topic><topic>Organs</topic><topic>Peptides</topic><topic>Radiation therapy</topic><topic>Radiology</topic><topic>Receptors</topic><topic>Short Communication</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freedman, Nanette</creatorcontrib><creatorcontrib>Sandström, Mattias</creatorcontrib><creatorcontrib>Kuten, Jonathan</creatorcontrib><creatorcontrib>Shtraus, Natan</creatorcontrib><creatorcontrib>Ospovat, Inna</creatorcontrib><creatorcontrib>Schlocker, Albert</creatorcontrib><creatorcontrib>Even-Sapir, Einat</creatorcontrib><collection>SpringerOpen(OpenAccess)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>EJNMMI physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freedman, Nanette</au><au>Sandström, Mattias</au><au>Kuten, Jonathan</au><au>Shtraus, Natan</au><au>Ospovat, Inna</au><au>Schlocker, Albert</au><au>Even-Sapir, Einat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Personalized radiation dosimetry for PRRT—how many scans are really required?</atitle><jtitle>EJNMMI physics</jtitle><stitle>EJNMMI Phys</stitle><addtitle>EJNMMI Phys</addtitle><date>2020-05-11</date><risdate>2020</risdate><volume>7</volume><issue>1</issue><spage>26</spage><epage>26</epage><pages>26-26</pages><artnum>26</artnum><issn>2197-7364</issn><eissn>2197-7364</eissn><abstract>Purpose Over recent years, peptide receptor radiotherapy (PRRT) has been recognized as an effective treatment for patients with metastatic neuroendocrine tumors (NETs). Personalized dosimetry can contribute to improve the outcome of peptide receptor radiotherapy (PRRT) in patients with metastatic NETs. Dosimetry can aid treatment planning, ensuring that absorbed dose to vulnerable normal organs (kidneys and bone marrow) does not exceed safe limits over serial treatments, and that absorbed dose to tumor is sufficient. Absorbed dose is estimated from a series of post-treatment SPECT/CT images. Total self-dose is proportional to the integral under the time activity concentration curve (TACC). Method dependence of image-based absorbed dose calculations has been previously investigated, and we set out here to extend previous work by examining implications of number of data points in the TACC and the numerical integration methods used in estimating absorbed dose. Methods In this retrospective study, absorbed dose estimates and effective half-lives were calculated by fitting curves to TACCs for normal organs and tumors in 30 consecutive patients who underwent a series of 4 post-treatment SPECT/CT scans at 4 h, 24 h, 4–5 days, and 1 week following 177 Lu-DOTATATE PRRT. We examined the effects of including only 2 or 3 rather than all 4 data points in the TACC, and the effect of numerical integration method (mono-exponential alone or in combination with trapezoidal rule) on the absorbed dose and half-life estimates. Our current method is the combination of trapezoidal rule over the first 24 h, with mono-exponential fit thereafter extrapolated to infinity. The other methods were compared to this current method. Results Differences in absorbed dose and effective half-life between the current method and estimates based only on the second, third, and fourth scans were very small (mean differences &lt; 2.5%), whereas differences between the current method and 4-point mono-exponential fit were higher (mean differences &lt; 5%) with a larger range. It appears that in a 4-point mono-exponential fit the early (4 h) time point may skew results, causing some large errors. Differences between the current method and values based on only 2 time points were relatively small (mean differences &lt; 3.5%) when the 24 h and 1 week scans were used, but when the 24 h and 4–5 days scans, or the 4–5 days and 1 week scans were used, differences were greater. Conclusion This study indicates that for 177 Lu-DOTATATE PRRT, accurate estimates of absorbed dose for organs and tumors may be estimated from scans at 24 h, 72 h, and 1 week post-treatment without an earlier scan. It may even be possible to cut out the 72 h scan, though the uncertainty increases. However, further work on more patients is required to validate this.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32394075</pmid><doi>10.1186/s40658-020-00293-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2197-7364
ispartof EJNMMI physics, 2020-05, Vol.7 (1), p.26-26, Article 26
issn 2197-7364
2197-7364
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cd307c1f09cd4567a520d61080c066ec
source PubMed (Medline); Publicly Available Content Database; Springer Nature - SpringerLink Journals - Fully Open Access
subjects 177Lu-DOTATATE
Applied and Technical Physics
Bone marrow
Computational Mathematics and Numerical Analysis
Computed tomography
Curve fitting
Data points
Dosimeters
Dosimetry
Engineering
Estimates
Half-life
Imaging
Lutetium isotopes
Mathematical analysis
Medical imaging
Medicine
Medicine & Public Health
Metastasis
Method dependence
Methods
Neuroendocrine tumors
Nuclear Medicine
Numerical integration
Numerical methods
Organs
Peptides
Radiation therapy
Radiology
Receptors
Short Communication
Tumors
title Personalized radiation dosimetry for PRRT—how many scans are really required?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A50%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Personalized%20radiation%20dosimetry%20for%20PRRT%E2%80%94how%20many%20scans%20are%20really%20required?&rft.jtitle=EJNMMI%20physics&rft.au=Freedman,%20Nanette&rft.date=2020-05-11&rft.volume=7&rft.issue=1&rft.spage=26&rft.epage=26&rft.pages=26-26&rft.artnum=26&rft.issn=2197-7364&rft.eissn=2197-7364&rft_id=info:doi/10.1186/s40658-020-00293-z&rft_dat=%3Cproquest_doaj_%3E2401805530%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c644t-3d5e9c13eb4f1ff80378e72e5af75fdc96acf94379c9e40ea4965f89843bb91a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2400891079&rft_id=info:pmid/32394075&rfr_iscdi=true